Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Martin D. Berger

University Name

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Biostatistics

60%

Immunology

60%

Cancer Biology

100%

Oncology

50%

Colorectal Cancer

30%

Medical Science

30%

Solid Tumor

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles29

Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.

Article Link

Year:

2024

Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy of Esophageal Cancer: First Clinical Experience and Dosimetric Benefits.

Article Link

Year:

2024

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)-SAKK 41/16.

Article Link

Year:

2024

Cancer and left atrial enlargement in patients with ischemic stroke.

Article Link

Year:

2024

Mortality in acute ischemic stroke patients with new cancer diagnosed during the index hospitalization versus after discharge.

Article Link

Year:

2024

Non-specific presentation of metastatic small bowel adenocarcinoma with diagnostic challenges.

Article Link

Year:

2024

The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition.

Article Link

Year:

2024

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (<i>DPYD</i>).

Article Link

Year:

2024

Prevalence of right-to-left shunt in stroke patients with cancer.

Article Link

Year:

2024

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

Article Link

Year:

2023

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Article Link

Year:

2023

Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomy.

Article Link

Year:

2023

The complexity of shapes; how the circularity of tumor nodules impacts prognosis in colorectal cancer.

Article Link

Year:

2023

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook.

Article Link

Year:

2023

Transient ischemic attacks in patients with active and occult cancer.

Article Link

Year:

2023

Watchful Waiting after Definitive Radiochemotherapy in Patients with Esophageal Cancer: Independent Predictors for Recurrence

Article Link

Year:

2023

Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related stroke.

Article Link

Year:

2023

Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?-A systematic review.

Article Link

Year:

2023

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.

Article Link

Year:

2023

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.

Article Link

Year:

2021

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

Article Link

Year:

2021

RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.

Article Link

Year:

2021

Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.

Article Link

Year:

2021

CCR5 is a potential therapeutic target for cancer.

Article Link

Year:

2021

Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.

Article Link

Year:

2021

Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.

Article Link

Year:

2021

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

Article Link

Year:

2020

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

Article Link

Year:

2020

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.

Article Link

Year:

2020

Collaborators16

Andreas Wicki

University of Zurich

SWITZERLAND

Carlo Largiader

University Hospital of Bern

SWITZERLAND

Giuseppe Masucci

Karolinska Institutet

SWEDEN

Christoph Kurmann

University Hospital of Bern

SWITZERLAND

Simon Jung

University Hospital of Bern

SWITZERLAND

Marc Van den Eynde

Associate Professor

Université catholique de Louvain

BELGIUM

Inti Zlobec

University of Bern

SWITZERLAND

Vanessa Banz

SWITZERLAND

Yu Sunakawa

St. Marianna University School of Medicine

JAPAN

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Francesco Ciompi

Associate Professor

Radboud University Medical Center

NETHERLANDS

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Universitari Vall d'Hebron

SPAIN

Luigi Laghi

Associate professor of gastroenterology

University of Parma

ITALY

Toshihiko Torigoe

Professor

Sapporo Medical University

JAPAN

Kristýna Němejcová

Všeobecná Fakultní Nemocnice v Praze

CZECH REPUBLIC

Chiara Cremolini

University Hospital of Pisa

ITALY

How do I reach out?

Meet Kite AI

Martin D. Berger

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles29

Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.

Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy of Esophageal Cancer: First Clinical Experience and Dosimetric Benefits.

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)-SAKK 41/16.

Cancer and left atrial enlargement in patients with ischemic stroke.

Mortality in acute ischemic stroke patients with new cancer diagnosed during the index hospitalization versus after discharge.

Non-specific presentation of metastatic small bowel adenocarcinoma with diagnostic challenges.

The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition.

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (&lt;i&gt;DPYD&lt;/i&gt;).

Prevalence of right-to-left shunt in stroke patients with cancer.

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomy.

The complexity of shapes; how the circularity of tumor nodules impacts prognosis in colorectal cancer.

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook.

Transient ischemic attacks in patients with active and occult cancer.

Watchful Waiting after Definitive Radiochemotherapy in Patients with Esophageal Cancer: Independent Predictors for Recurrence

Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related stroke.

Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?-A systematic review.

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.

Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.

CCR5 is a potential therapeutic target for cancer.

Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.

Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.

Collaborators16

Andreas Wicki

Carlo Largiader

Giuseppe Masucci

Christoph Kurmann

Simon Jung

Marc Van den Eynde

Inti Zlobec

Vanessa Banz

Yu Sunakawa

J. Jack Lee

Francesco Ciompi

Teresa Macarulla

Luigi Laghi

Toshihiko Torigoe

Kristýna Němejcová

Chiara Cremolini

How do I reach out?

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (<i>DPYD</i>).